On December 7, 2025, the National Healthcare Security Administration released the latest medical insurance catalog. Once announced, the news quickly flooded industry WeChat Moments. For every pharma company successfully included in the new catalog, this means a major improvement in product accessibility and patient benefit. It also means a sharply faster competitive rhythm, a fully reconstructed communication chain, and new tests around customer reach and content marketing. A new golden window for market expansion has opened.
However, entering the catalog is only the ticket. The real battle is the market education and refined operation that come next:
How can physicians and patients learn the reimbursement information in the shortest possible time, see it, find it, and be willing to use it?
Patients' reliance on large AI models is increasing rapidly, and information discovery is quickly moving toward large AI models. How can accurate product information appear in front of more patients?
The customer scope suddenly expands from tier-one and tier-two tertiary hospitals to broader and even grassroots medical institutions. How can teams quickly identify target customers precisely?
How can these customers be reached and educated quickly, accurately, and effectively? What are their views and obstacles?
Traditional promotion models struggle to support fast, personalized, and precise communication needs. How can awareness and understanding among large groups of new target HCPs be improved?
How can teams quickly produce personalized academic content suitable for HCPs at different stages?...
In other words, the actions pharma companies take during this next period will determine who can take off with the momentum of medical insurance expansion.
MeDomino focuses on AI + data-driven growth for the life sciences industry. Based on years of industry implementation experience, it provides pharma companies with a complete set of immediately actionable digital precision marketing solutions during this critical period.
01 How Much Do Large AI Models Know About Your Product?
Today, users increasingly rely on large AI model Q&A. Is your product being presented accurately and completely in mainstream large models?
Can your customers, including HCPs and patients, learn in a timely and accurate way which indications of your product are covered by medical insurance?
Can patients know immediately that "my disease can now be reimbursed"?
As everyone knows, large AI models draw from varied information sources and their answers can inevitably be wrong. In medicine, however, the harm caused by this problem is much more serious than in other industries. Incorrect or missing indication descriptions, delayed updates on new indications, missing reimbursement information, and similar issues can directly affect how patients and HCPs understand treatment options and may cause some patients to miss opportunities for treatment.
For pharma companies, effectively monitoring how products appear in large AI models, understanding the accuracy of AI model information in time, and quickly making corresponding optimizations have become important parts of digital and intelligent marketing.
MeDomino's GEO solution is not only monitoring; it is also content strategy.
MeDomino uses proprietary large AI models and combines them with each enterprise's specific needs to continuously monitor Q&A quality, score it quantitatively across multiple dimensions, guide subsequent content layout, and optimize continuously. It helps the life sciences industry adapt to AI-era search logic through AI technology. Through a fully intelligent closed loop, it quickly turns enterprise expertise into trusted knowledge sources that AI can understand, users can trust, and compliance can protect, directly integrating them into generative AI answers to achieve precise reach and efficiency improvement.
02 How Can Teams Precisely Identify and Effectively Expand Target HCP Lists?
After a product enters medical insurance, the market rapidly penetrates from core hospitals into a broader grassroots market and non-core tertiary hospitals. This means that beyond customers already being maintained, you need to cover more HCPs you have not reached before, including core departments, new patient-entry points, and physicians in lower-tier hospitals. But:
Do you really know which new HCPs you should reach?
Where are the thousands of mid-level and grassroots customers located?
Which HCPs truly have potential?
Medical insurance expansion is not about expanding lists by instinct. It depends on high-precision identification.
MeDomino has a nationwide database of 4 million HCPs, covering multiple disease areas and an industry-recognized standardized HCP data and evaluation system. It supports multidimensional, fine-grained target HCP screening and, combined with AI algorithms, helps pharma companies precisely locate and expand target HCP lists. It can accurately identify target customers such as investigators, speakers/listeners, article authors, and daily-visit targets according to business needs.
03 After Locking Onto Target HCPs, How Can Teams Achieve Efficient Personalized Academic Reach?
Once the list exists, do you know each physician's views? Do you understand their preferences and concerns? Are you familiar with their relationship circles? When pharma reps visit, what talking points should they use to open the conversation quickly and address the real pain point?
Large numbers of physicians outside tertiary hospitals are harder to judge, more scattered, and more unfamiliar than before. If you still use the same visit logic, the business may be rejected at the frontline. Understanding each target HCP's individual profile data is the prerequisite for effective reach.
MeDomino HCP360 is not an isolated profile system. It is full-chain AI-powered customer insight that enables precise operations across multiple scenarios and forms a closed loop of "data - profile - tag - strategy - reach - optimization."
04 How Can Teams Quickly Generate Personalized Content for HCPs at Each Stage to Support Market Expansion and Concept Implantation?
When your target customers expand from leading tertiary hospitals to a broader range of hospitals, you need to answer several questions: These physicians are not KOLs and may not pay attention to large academic conferences, so how do you move them? How can you generate large volumes of personalized and targeted content in a short time to influence them?
Physicians outside leading tertiary hospitals differ significantly in clinical concerns, learning habits, and patient challenges. What they need is content they can understand, use, implement, and apply to real scenarios. Meanwhile, large AI models are also important information sources for patients in lower-tier markets.
Content production speed will directly become your competitive speed. If you cannot do it, your competitors certainly can.
MeDomino AIGC tools fully use your enterprise-level content assets, rapidly integrate and reconstruct content with AI, and generate highly personalized learning materials and promotional assets for physicians at all levels while meeting regulatory requirements. They enable truly individualized content and significantly improve content production efficiency.
